{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:34:32Z","timestamp":1793687672798,"version":"4.5.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012355","name":"United European Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012355","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1053\/j.gastro.2021.02.068","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T10:02:42Z","timestamp":1614938562000},"page":"2340-2353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":236,"title":["Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease"],"prefix":"10.1053","volume":"160","author":[{"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Leszczyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dudkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Gawdis-Wojnarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldis","family":"Pukitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Horynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Kierkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Joon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hye","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Rim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seul Gi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6647-6325","authenticated-orcid":false,"given":"Byong Duk","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2021.02.068_bib1","first-page":"228","article-title":"Inflammatory bowel disease - one entity with many molecular faces","volume":"14","author":"Szyma\u0144ska","year":"2019","journal-title":"Prz Gastroenterol"},{"key":"10.1053\/j.gastro.2021.02.068_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(15)00465-1","article-title":"Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study","volume":"387","author":"Cleynen","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.02.068_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14712598.2018.1469620","article-title":"Progress with infliximab biosimilars for inflammatory bowel disease","volume":"18","author":"Kurti","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.gastro.2021.02.068_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.02.068_bib5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.02.068_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2021.02.068_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.02.068_bib8","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.02.068_bib9","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2021.02.068_bib10","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/14712598.2019.1653848","article-title":"CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease","volume":"19","author":"Albshesh","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.gastro.2021.02.068_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00384-019-03354-7","article-title":"An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease","volume":"34","author":"Ebada","year":"2019","journal-title":"Int J Colorectal Dis"},{"key":"10.1053\/j.gastro.2021.02.068_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"10.1053\/j.gastro.2021.02.068_bib14","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous absorption of biotherapeutics: knowns and unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1053\/j.gastro.2021.02.068_bib15","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ibd.21888","article-title":"Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)","volume":"18","author":"Vavricka","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.02.068_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-10-1","article-title":"How do patients with inflammatory bowel disease want their biological therapy administered?","volume":"10","author":"Allen","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2021.02.068_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3346\/jkms.2017.32.1.85","article-title":"Physicians should provide shared decision-making for anti-TNF therapy to inflammatory bowel disease patients","volume":"32","author":"Cha","year":"2017","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1053\/j.gastro.2021.02.068_bib18","first-page":"391","article-title":"Factors contributing to the preference of Korean patients with Crohn's disease when selecting an anti-tumor necrosis factor agent (CHOICE study)","volume":"10","author":"Kim","year":"2016","journal-title":"Gut Liver"},{"key":"10.1053\/j.gastro.2021.02.068_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1055\/s-0034-1368173","article-title":"Subcutaneous administration of monoclonal antibodies in oncology","volume":"74","author":"Jackisch","year":"2014","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1053\/j.gastro.2021.02.068_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: How do we get there?","volume":"286","author":"Viola","year":"2018","journal-title":"J\u00a0Control Release"},{"key":"10.1053\/j.gastro.2021.02.068_bib21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11845-018-1925-8","article-title":"The non-drug costs associated with the administration of an intravenous biologic treatment in the hospital setting","volume":"188","author":"Cronin","year":"2019","journal-title":"Ir J Med Sci"},{"key":"10.1053\/j.gastro.2021.02.068_bib23","doi-asserted-by":"crossref","first-page":"S066","DOI":"10.1093\/ecco-jcc\/jjy222.096","article-title":"A\u00a0novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a Phase I open-label randomised controlled trial in patients with active Crohn\u2019s disease","volume":"13","author":"Reinisch","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2021.02.068_bib24","doi-asserted-by":"crossref","first-page":"S-1096","DOI":"10.1016\/S0016-5085(19)39701-X","article-title":"A\u00a0novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomized controlled trial in patients with active Crohn's disease [abstract Tu1715]","volume":"156","author":"Ye","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.02.068_bib25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.02.068_bib26","first-page":"1435","article-title":"Biologic concentration testing in inflammatory bowel disease","volume":"21","author":"Vaughn","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2021.02.068_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2018-eular.1810","article-title":"Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase I\/III randomised controlled trial [abstract THU0191]","volume":"77","author":"Westhovens","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.02.068_bib28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/annrheumdis-2019-eular.1094","article-title":"A\u00a0novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year results from a Part 1 of Phase I\/III randomized controlled trial in patients with active rheumatoid arthritis [abstract FRI0128]","volume":"78","author":"Yoo","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2021.02.068_bib29","unstructured":"Westhovens R, Wiland P, Zawadzki M, et\u00a0al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial [published online ahead of print November 23, 2020]. Rheumatology (Oxford) doi: 10.1093\/rheumatology\/keaa580.."},{"key":"10.1053\/j.gastro.2021.02.068_bib32","first-page":"2342187","article-title":"Unraveling the effect of immunogenicity on the PK\/PD, efficacy, and safety of therapeutic proteins","volume":"2016","author":"Smith","year":"2016","journal-title":"J\u00a0Immunol Res"},{"key":"10.1053\/j.gastro.2021.02.068_bib33","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2021.02.068_bib34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaci.2015.03.013","article-title":"Monoclonal antibodies in excess: a simple way to avoid immunogenicity in patients?","volume":"136","author":"Chaigne","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1053\/j.gastro.2021.02.068_bib35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4049\/jimmunol.1000422","article-title":"A\u00a0novel strategy to reduce the immunogenicity of biological therapies","volume":"185","author":"Somerfield","year":"2010","journal-title":"J\u00a0Immunol"},{"key":"10.1053\/j.gastro.2021.02.068_bib36","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2019.08.009","article-title":"Infliximab\u2013tumor necrosis factor complexes elicit formation of anti-drug antibodies","volume":"157","author":"Bar-Yoseph","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521004741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508521004741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:48:18Z","timestamp":1762163298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508521004741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0016508521004741"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2021.02.068","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2021.02.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}